To sum up, the targeted inhibition of MAP2K6, PAK1, MNK1, FGF2, PIN1, PBK, and the targeted activation of DAPK1, BLU, miR-124 in the targeted therapy of NPC could be a potential therapeutic strategy through the MAPK pathway. This evidence concerns the gene FGF2 and nasopharyngeal carcinoma.